Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 "Adaptive pathways" to drug authorisation: adapting to industry?

Literature DB >> 27531201

"Adaptive pathways" to drug authorisation: adapting to industry?

Courtney Davis¹, Joel Lexchin², Tom Jefferson³, Peter Gøtzsche⁴, Martin McKee⁵.

Abstract

Mesh：

Year: 2016 PMID： 27531201 DOI： 10.1136/bmj.i4437

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

1. Medicines Save, Medicines Kill.

Authors: Joel Lexchin
Journal: Drug Saf Date: 2017-06 Impact factor: 5.606

2. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.

Authors: Kim Boesen; Peter C Gøtzsche; John P A Ioannidis
Journal: Epidemiol Psychiatr Sci Date: 2021-04-30 Impact factor: 6.892

3. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.

Authors: Michael Ermisch; Anna Bucsics; Patricia Vella Bonanno; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Jurij Fürst; Kristina Garuolienė; Martin van der Graaff; Jolanta Gulbinovič; Alan Haycox; Jan Jones; Roberta Joppi; Ott Laius; Irene Langner; Antony P Martin; Vanda Markovic-Pekovic; Laura McCullagh; Einar Magnusson; Ellen Nilsen; Gisbert Selke; Catherine Sermet; Steven Simoens; Robert Sauermann; Ad Schuurman; Ricardo Ramos; Vera Vlahovic-Palcevski; Corinne Zara; Brian Godman
Journal: Front Pharmacol Date: 2016-09-28 Impact factor: 5.810

Review 4. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Authors: Patricia Vella Bonanno; Michael Ermisch; Brian Godman; Antony P Martin; Jesper Van Den Bergh; Liudmila Bezmelnitsyna; Anna Bucsics; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Irene Eriksson; Jurij Fürst; Mohamed Gad; Ieva Greičiūtė-Kuprijanov; Martin van der Graaff; Jolanta Gulbinovic; Jan Jones; Roberta Joppi; Marija Kalaba; Ott Laius; Irene Langner; Ileana Mardare; Vanda Markovic-Pekovic; Einar Magnusson; Oyvind Melien; Dmitry O Meshkov; Guenka I Petrova; Gisbert Selke; Catherine Sermet; Steven Simoens; Ad Schuurman; Ricardo Ramos; Jorge Rodrigues; Corinne Zara; Eva Zebedin-Brandl; Alan Haycox
Journal: Front Pharmacol Date: 2017-08-23 Impact factor: 5.810

5. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

Authors: Joel Lexchin
Journal: BMJ Open Date: 2017-10-22 Impact factor: 2.692

Review 6. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?

Authors: Ana Rath; Valérie Salamon; Sandra Peixoto; Virginie Hivert; Martine Laville; Berenice Segrestin; Edmund A M Neugebauer; Michaela Eikermann; Vittorio Bertele; Silvio Garattini; Jørn Wetterslev; Rita Banzi; Janus C Jakobsen; Snezana Djurisic; Christine Kubiak; Jacques Demotes-Mainard; Christian Gluud
Journal: Trials Date: 2017-11-22 Impact factor: 2.279

"Adaptive pathways" to drug authorisation: adapting to industry?

1. Medicines Save, Medicines Kill.

2. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.

3. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.

Review 4. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

5. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

Review 6. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?

7. Innovative regenerative medicines in the EU: a better future in evidence?

8. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.

9. Cancer drugs: high price, uncertain value.

10. Patients not patents: Drug research and development as a public enterprise.